Research and Markets: Cost-Contained Regulatory Compliance: For the Pharmaceutical, Biologics, and Medical Device Industri

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/852d5d/costcontained_reg) has announced the addition of John Wiley and Sons Ltd's new book "Cost-Contained Regulatory Compliance: For the Pharmaceutical, Biologics, and Medical Device Industries" to their offering.

This book guides the reader through FDA regulation guidelines and outlines a comprehensive strategy for cost reduction in regulatory affairs and compliance. This book explains six strategies to cost-effectively comply with FDA regulations while maintaining product safety and improving public access through cost controls. It provides useful and practical guidance through industry case studies from pharmaceutical, biotech, and medical device industries.

Key Topics Covered:

  • PREFACE.
  • Chapter 1. Controlling Regulatory Costs.
  • Chapter 2. Clear Operation Definitions of Requirements.
  • Chapter 3. Pre-Regulatory Audits.
  • Chapter 4. Quality by Design.
  • Chapter 5. Outsourcing.
  • Chapter 6. Electronic Submissions.
  • Chapter 7. EMEA/FDA Inspections.
  • Chapter 8. Managing FDA Inspections.
  • Chapter 9. Risk Assessment.
  • Chapter 10. Cases.
  • Chapter 11. Cost Containment Analysis.
  • Chapter 12. Managing Regulation In Times of Chaos.
  • Chapter 13. International Regulation.
  • Chapter 14. Cost Contained Regulatory Compliance.
  • Chapter 15. Future.
  • BIBLIOGRAPHY.
  • INDEX.

Author:

  • SANDY WEINBERG, PhD, is a professor of healthcare management at Clayton State University in Atlanta and an international regulatory consultant. He has thirty-five years' regulatory experience, including global executive responsibility at GE Healthcare and Tikvah Therapeutics. Dr. Weinberg has written thirteen books including, most recently, Guidebook for Drug Regulatory Submissions, also from Wiley.

For more information visit http://www.researchandmarkets.com/research/852d5d/costcontained_reg



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.